POLA1 and diffuse large B-cell lymphoma: Combining pola with rituximab or obinutuzumab plus cyclophosphamide, doxorubicin, and prednisone (R/G-CHP) has a manageable safety profile and promising preliminary clinical activity in newly diagnosed DLBCL [19], supporting the initiation of a phase III trial comparing pola + R-CHP to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).